Literature DB >> 24982078

In vitro activities of nine antifungal drugs and their combinations against Phialophora verrucosa.

Yali Li1, Zhe Wan1, Ruoyu Li2.   

Abstract

The in vitro activities of nine antifungal drugs and their combinations against 31 clinical and 15 environmental Phialophora verrucosa strains were tested. The MIC90/90% minimum effective concentration (MIC/MEC90) values (μg/ml) across all strains were as follows: for terbinafine, 0.25; for posaconazole, 0.5; for voriconazole, 1; for itraconazole, 2; for amphotericin B, 4; for caspofungin and micafungin, 16; and for fluconazole and flucytosine, 64. The highest synergy was shown by the combination of itraconazole plus caspofungin (with synergy against 100% of the 31 clinical strains), followed by amphotericin B plus flucytosine (45.2%) and itraconazole plus terbinafine or micafungin (25.8% or 12.9%, respectively).
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24982078      PMCID: PMC4135824          DOI: 10.1128/AAC.02875-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.

Authors:  Maria Drogari-Apiranthitou; Foteini-Despina Mantopoulou; Anna Skiada; Lambrini Kanioura; Maria Grammatikou; Georgia Vrioni; Aggeliki Mitroussia-Ziouva; Athanassios Tsakris; George Petrikkos
Journal:  J Antimicrob Chemother       Date:  2012-04-25       Impact factor: 5.790

2.  In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds.

Authors:  Fernanda Simas Corrêa Biancalana; Luzia Lyra; Angélica Zaninelli Schreiber
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

3.  In vitro antifungal susceptibility of Cladophialophora carrionii, an agent of human chromoblastomycosis.

Authors:  S Deng; G S de Hoog; H Badali; L Yang; M J Najafzadeh; B Pan; I Curfs-Breuker; J F Meis; W Liao
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

4.  Endophthalmitis caused by Phialophora verrucosa and Streptococcus intermedius: a case report.

Authors:  Shiying Sun; Gongqiang Yuan; Ge Zhao; Hao Chen; Bin Yu
Journal:  Med Mycol       Date:  2010-08-31       Impact factor: 4.076

5.  The clinical efficacy and safety of micafungin-itraconazole combination therapy in patients with pulmonary aspergilloma.

Authors:  Masaki Fujita; Yoshiaki Tao; Akira Kajiki; Hiroshi Ouchi; Eiji Harada; Satoshi Ikegame; Takemasa Matsumoto; Junji Uchino; Kentaro Watanabe; Yoichi Nakanishi
Journal:  J Infect Chemother       Date:  2012-02-22       Impact factor: 2.211

6.  In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.

Authors:  Mohammad J Najafzadeh; Hamid Badali; Maria Teresa Illnait-Zaragozi; G Sybren De Hoog; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

7.  In vitro susceptibility of chromoblastomycosis agents to five antifungal drugs and to the combination of terbinafine and amphotericin B.

Authors:  Tatiane C Daboit; Cibele Massotti Magagnin; Daiane Heidrich; Laura Czekster Antochevis; Suelen Vigolo; Lúcia Collares Meirelles; Karine Alves; Maria L Scroferneker
Journal:  Mycoses       Date:  2013-07-29       Impact factor: 4.377

Review 8.  Generalized subcutaneous phaeohyphomycosis caused by Phialophora verrucosa: report of a case and review of literature.

Authors:  Zhongsheng Tong; Sharon C-A Chen; Liuqing Chen; Bilin Dong; Ruoyu Li; Zhimin Hu; Ping Jiang; Dongsheng Li; Yiqun Duan
Journal:  Mycopathologia       Date:  2013-02-08       Impact factor: 2.574

9.  Recalcitrant primary subcutaneous phaeohyphomycosis due to Phialophora verrucosa.

Authors:  Lu-juan Gao; Jin Yu; Duan-li Wang; Ruo-yu Li
Journal:  Mycopathologia       Date:  2012-12-21       Impact factor: 2.574

10.  In vitro activities of nine antifungal drugs against 81 Phialophora and Cyphellophora isolates.

Authors:  Peiying Feng; M Javad Najafzadeh; Jiufeng Sun; Sarah Ahmed; Liyan Xi; G Sybren de Hoog; Wei Lai; Chun Lu; Corné H Klaassen; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

View more
  6 in total

1.  Answer to February 2020 Photo Quiz.

Authors:  Camille M Webb; Lindy Ross; Seena Monjazeb; Brandon Goodwin; Ping Ren
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

2.  In Vitro Activities of Ravuconazole and Isavuconazole against Dematiaceous Fungi.

Authors:  Hailin Zheng; Nana Song; Huan Mei; Jiacheng Dong; Dongmei Li; Xiaofang Li; Weida Liu
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

3.  Effectiveness of voriconazole and corneal cross-linking on Phialophora verrucosa keratitis: a case report.

Authors:  Marisa Taechajongjintana; Ngamjit Kasetsuwan; Usanee Reinprayoon; Sirinuch Sawanwattanakul; Phattrawan Pisuchpen
Journal:  J Med Case Rep       Date:  2018-08-19

4.  Chromoblastomycosis Caused by Phialophora-Proven Cases from Mexico.

Authors:  Sarah A Ahmed; Alexandro Bonifaz; Gloria M González; Leandro F Moreno; Nickolas Menezes da Silva; Vania A Vicente; Ruoyu Li; Sybren de Hoog
Journal:  J Fungi (Basel)       Date:  2021-01-29

5.  New possibilities for chromoblastomycosis and phaeohyphomycosis treatment: identification of two compounds from the MMV Pathogen Box® that present synergism with itraconazole.

Authors:  Rowena Alves Coelho; Gabriela Machado Alves; Maria Helena Galdino Figueiredo-Carvalho; Fernando Almeida-Silva; Gabriela Rodrigues de Souza; Maria Cristina da Silva Lourenço; Fábio Brito-Santos; Ana Claudia Fernandes Amaral; Rodrigo Almeida-Paes
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-09-12       Impact factor: 2.747

6.  Molecular identification and antifungal susceptibility profiles of clinical strains of Fonsecaea spp. isolated from patients with chromoblastomycosis in Rio de Janeiro, Brazil.

Authors:  Rowena Alves Coelho; Fábio Brito-Santos; Maria Helena Galdino Figueiredo-Carvalho; Juliana Vitoria Dos Santos Silva; Maria Clara Gutierrez-Galhardo; Antonio Carlos Francesconi do Valle; Rosely Maria Zancopé-Oliveira; Luciana Trilles; Wieland Meyer; Dayvison Francis Saraiva Freitas; Rodrigo Almeida-Paes
Journal:  PLoS Negl Trop Dis       Date:  2018-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.